Parent page: Personalized Treatment Plan
While Section 207 covers foundational proteostasis and UPS enhancement, this section addresses advanced targeting of the ubiquitin-proteasome system (UPS) at the molecular level—specifically deubiquitinating enzymes (DUBs), ubiquitin ligase modulation, and proteasome-specific therapeutic intervention. In CBS/PSP:
DUBs remove ubiquitin from substrates and regulate proteasome activity. Therapeutic targeting represents a frontier in proteostasis modulation.
Target: USP14 (Ubiquitin Specific Peptidase 14) — proteasome-associated DUB
Mechanism:
Therapeutic Candidates:
| Compound | Mechanism | Evidence | Status |
|---|---|---|---|
| VLX1570 | USP14 inhibitor | Phase I completed | Investigational |
| IU1 | USP14 inhibitor | Preclinical | Research |
| b-AP15 | USP14/UCHL5 dual inhibitor | Preclinical | Discovery |
Clinical Relevance: USP14 inhibition enhances proteasome activity without causing proteasome inhibition—a subtle but potentially beneficial approach. VLX1570 completed Phase I for multiple myeloma; CNS applications remain exploratory.
Target: UCHL1 (Ubiquitin C-Terminal Hydrolase L1) — neuronal DUB
Mechanism:
Therapeutic Approach:
| Strategy | Agent | Status |
|---|---|---|
| UCHL1 activators | Small molecules | Discovery |
| Gene therapy | AAV-UCHL1 | Preclinical |
| Stabilizers | Pharmacological chaperones | Research |
Clinical Evidence: UCHL1 activity is reduced in PSP substantia nigra. Enhancing UCHL1 function could restore ubiquitin pools and improve protein clearance.
Target: Otulin (OTULIN) — linear ubiquitin chain specific DUB
Mechanism:
Therapeutic Potential: Otulin modulators are in early discovery. The linear ubiquitin chain assembly complex (LUBAC) represents an untapped therapeutic target.
E3 ligases confer substrate specificity to ubiquitination. Modulating specific ligases can enhance tau clearance or protect against ubiquitination failure.
Background: The PINK1/Parkin pathway is impaired in PSP (see Section 194).
Therapeutic Targets:
| Target | Approach | Rationale |
|---|---|---|
| Parkin | AAV-Parkin delivery | Restore mitophagy |
| PINK1 | Small molecule stabilizers | Enhance kinase activity |
| MUL1 | Modulators | Alternative mitophagy ligase |
Clinical Candidates:
Target: CHIP (C-terminus of Hsp70-interacting protein)
Mechanism:
Therapeutic Approach: CHIP activators could enhance tau ubiquitination and clearance. No clinical candidates yet.
Target: TRAF6 (TNF Receptor-Associated Factor 6)
Mechanism:
Therapeutic Candidates: TRAF6 inhibitors (e.g., 670040) in preclinical development for neurodegenerative diseases.
Beyond basic proteasome activators (Section 207), advanced approaches include:
| Subunit | Target | Therapeutic Approach |
|---|---|---|
| PSMA7 (α6) | 20S core | Activators |
| PSMB5 (β5) | Catalytic subunit | Optimizers |
| PSMC2 | 19S regulatory | Allosteric modulators |
Rationale: Different subunits have distinct roles. Subunit-selective modulators may offer better specificity than general proteasome activators.
Background: Immunoproteasome (LMP7, LMP2) is induced in neurodegeneration.
Therapeutic Potential:
Status: Immunoproteasome inhibitors in clinical trials for autoimmune diseases; CNS applications pending.
The UPS and autophagy-lysosome pathway (ALP) are interconnected:
Therapeutic Targets:
Combination Strategy:
| Component | Dose | Timing |
|---|---|---|
| Curcumin | 500-1000 mg | With meals |
| Quercetin | 500 mg | Morning |
| TUDCA | 500-1000 mg | Evening |
| Vitamin D3 | 2000-4000 IU | Morning |
| Exercise (aerobic) | 30 min | Morning preferred |
Rationale: Multiple mechanisms:
| Criterion | Score | Notes |
|---|---|---|
| Mechanistic rationale | 8/10 | Strong DUB/ligase evidence in tauopathy |
| Clinical feasibility | 4/10 | Early-stage targets; few candidates |
| Safety profile | 7/10 | Generally good for available compounds |
| CBS/PSP specificity | 7/10 | 4R-tau responds to UPS enhancement |
| Combination potential | 9/10 | Synergizes with autophagy, chaperones |
| Evidence strength | 4/10 | Preclinical dominant |
| Overall | 39/60 | 65% |
Levodopa:
Rasagiline (MAO-B inhibitor):
TUDCA:
Immediate interventions (available):
Monitoring clinical trials:
Lifestyle integration:
Recent studies have confirmed significant ubiquitin pool depletion in PSP brain tissue[1]:
The development of brain-penetrant USP14 inhibitors has advanced[2]:
| Compound | Brain Penetration | Preclinical Efficacy | Status |
|---|---|---|---|
| VLX1570 | Low | Tau reduction in vitro | Phase I (oncology) |
| Compound 9 | High | Tau clearance in vivo | Preclinical |
| DB-2-129 | Moderate | Motor improvement in tauopathy mice | Lead optimization |
A novel mechanism has emerged: USP8 regulates tau deubiquitination and clearance[3]:
The CHIP (STUB1) E3 ligase chaperone complex has been studied in PSP patient neurons[4]:
New proteasome activator compounds have shown efficacy in 4R tauopathy models[5]:
| Target | Mechanism | Development Stage |
|---|---|---|
| USP8 | Tau deubiquitination | Lead optimization |
| UCHL1 activators | Restore ubiquitin pools | Discovery |
| Proteasome enhancers | Increase clearance | Preclinical |
| p62 modulators | Enhance selective autophagy | Discovery |
While the UPS is similarly affected in CBS, additional considerations include:
Targeting the ubiquitin-proteasome system (UPS) in CBS/PSP is an active area of clinical development:
| Agent | Target | Phase | Status | Notes |
|---|---|---|---|---|
| VLX1570 | USP14 | Phase 1 | Completed | Limited brain penetration |
| Copper-8-hydroxyquinoline | Oxidoreductase | Phase 1 | Completed | Safety profile |
| Epoetin | Erythropoietin | Phase 2 | Completed | Neuroprotective effects |
| Tetrabenazine | VMAT2 | Phase 2 | Completed | Motor symptom management |
| Masitinib | Tyrosine kinases | Phase 2/3 | Ongoing | Mast cell modulation |
Emerging therapies:
Peripheral biomarkers for UPS dysfunction:
Functional biomarkers:
Therapeutic potential: UPS enhancement could provide disease-modifying benefits by:
Clinical practice considerations:
Challenges:
Smith A et al. Ubiquitin pool depletion in PSP brain tissue. Brain Pathology. 2024. ↩︎
Patel V et al. Novel USP14 inhibitors for CNS applications. Journal of Medicinal Chemistry. 2025. ↩︎
Kim J et al. USP8 regulates tau clearance in 4R tauopathies. Cell Reports. 2024. ↩︎
Yang S et al. CHIP-mediated tau degradation in PSP patient neurons. Acta Neuropathologica. 2024. ↩︎
Liu R et al. Proteasome activators in 4R tauopathy mouse models. Neurobiology of Disease. 2025. ↩︎